PT  - JOURNAL ARTICLE
AU  - Schultz, Bárbara M
AU  - Melo-González, Felipe
AU  - Duarte, Luisa F
AU  - Gálvez, Nicolás MS
AU  - Pacheco, Gaspar A
AU  - Soto, Jorge A
AU  - Berríos-Rojas, Roslye V
AU  - González, Liliana A
AU  - Moreno-Tapia, Daniela
AU  - Rivera-Pérez, Daniela
AU  - Ríos, Mariana
AU  - Vázquez, Yaneisi
AU  - Hoppe-Elsholz, Guillermo
AU  - Vallejos, Omar P
AU  - Iturriaga, Carolina
AU  - Urzua, Marcela
AU  - Navarrete, María S
AU  - Rojas, Álvaro
AU  - Fasce, Rodrigo
AU  - Fernández, Jorge
AU  - Mora, Judith
AU  - Ramírez, Eugenio
AU  - Gaete-Argel, Aracelly
AU  - Acevedo, Mónica
AU  - Valiente-Echeverría, Fernando
AU  - Soto-Rifo, Ricardo
AU  - Weiskopf, Daniela
AU  - Grifoni, Alba
AU  - Sette, Alessandro
AU  - Zeng, Gang
AU  - Meng, Weining
AU  - ,
AU  - González-Aramundiz, José V
AU  - González, Pablo A
AU  - Abarca, Katia
AU  - Kalergis, Alexis M
AU  - Bueno, Susan M
TI  - A booster dose of an inactivated SARS-CoV-2 vaccine increases neutralizing antibodies and T cells that recognize Delta and Omicron variants of concern
AID  - 10.1101/2021.11.16.21266350
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2021.11.16.21266350
4099  - http://medrxiv.org/content/early/2022/02/07/2021.11.16.21266350.short
4100  - http://medrxiv.org/content/early/2022/02/07/2021.11.16.21266350.full
AB  - Background CoronaVac® is an inactivated SARS-CoV-2 vaccine approved by the World Health Organization. Previous studies reported increased levels of neutralizing antibodies and specific T cells two- and four-weeks after two doses of CoronaVac®, but the levels of neutralizing antibodies are reduced at six to eight months after two doses. Here we report the effect of a booster dose of CoronaVac® on the anti-SARS-CoV-2 immune response generated against variants of concern (VOC) Delta and Omicron in adults participating in a phase 3 clinical trial in Chile.Methods Volunteers immunized with two doses of CoronaVac® in a four-week interval received a booster dose of the same vaccine between twenty-four and thirty weeks after the 2nd dose. Four weeks after the booster dose, neutralizing antibodies and T cell responses were measured. Neutralization capacities and T cell activation against VOC Delta and Omicron were detected at four weeks after the booster dose.Findings We observed a significant increase in neutralizing antibodies at four weeks after the booster dose. We also observed an increase in CD4+ T cells numbers over time, reaching a peak at four weeks after the booster dose. Furthermore, neutralizing antibodies and SARS-CoV-2 specific T cells induced by the booster showed activity against VOC Delta and Omicron.Interpretation Our results show that a booster dose of CoronaVac® increases the anti-SARS-CoV-2 humoral and cellular immune responses in adults. Immunity induced by a booster dose of CoronaVac® is active against VOC, suggesting an effective protection.Competing Interest StatementZG and MW are SINOVAC employees and contributed to the conceptualization of the study (clinical protocol and eCRF design) and did not participate in the analysis or interpretation of the data presented in the manuscript. La Jolla Institute for Immunology (LJI) has filed for patent protection for various aspects of T cell epitope and vaccine design work. All other authors declare no conflict of interest. The authors declare that this study received the investigational product (placebo and vaccines) from the company SINOVAC Biotech. Clinical TrialNCT04651790Funding StatementThe CoronaVac03CL Study was funded by The Ministry of Health, Government of Chile, the Confederation of Production and Commerce (CPC), Chile and SINOVAC Biotech. NIH NIAID, under Contract 75N93021C00016, supports AS and Contract 75N9301900065 supports AS, AG and DW. The National Agency for Research and Development (ANID) through the Fondo Nacional de Desarrollo Cient&lacutefico y Tecnol&oacutegico (FONDECYT) grants 1190156 and 1211547 supports RSR and FVE, respectively. The Millennium Institute on Immunology and Immunotherapy, ANID - Millennium Science Initiative Program ICN09_016 (former P09/016-F) supports RSR, VFE, SMB, KA, PAG and AMK; The Innovation Fund for Competitiveness FIC-R 2017 (BIP Code: 30488811-0) supports SMB, PAG and AMK.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Blood samples were obtained from volunteers recruited in the clinical trial CoronaVac03CL (clinicaltrials.gov #NCT04651790) carried out in Chile starting in November 2020. The Institutional Scientific Ethical Committee of Health Sciences reviewed and approved the study protocol at the Pontificia Universidad Cat&oacutelica de Chile (#200708006). Trial execution was approved by the Chilean Public Health Institute (#24204/20) and was conducted according to the current Tripartite Guidelines for Good Clinical Practices, the Declaration of Helsinki and local regulations. Informed consent was obtained from all volunteers upon enrollment. Website: http://eticayseguridad.uc.cl/comite-etico-cientifico-facultad-de-medicina-uc.html). I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors